Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/125—Picornaviridae, e.g. calicivirus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5252—Virus inactivated (killed)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5258—Virus-like particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
  • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/70—Multivalent vaccine
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/32011—Picornaviridae
  • C12N2770/32311—Enterovirus
  • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/32011—Picornaviridae
  • C12N2770/32311—Enterovirus
  • C12N2770/32323—Virus like particles [VLP]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/32011—Picornaviridae
  • C12N2770/32311—Enterovirus
  • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/32011—Picornaviridae
  • C12N2770/32311—Enterovirus
  • C12N2770/32361—Methods of inactivation or attenuation
  • C12N2770/32363—Methods of inactivation or attenuation by chemical treatment

Definitions

• Sequence Listing is provided herewith as a Sequence Listing XML, “PRVN-V003WO_SEQ_LIST” created on October 21, 2022 and having a size of 5 KB.
• the contents of the Sequence Listing XML are incorporated by reference herein in their entirety.
• Coxsackievirus Group B is a member of the family Picornaviridae, genus Enterovirus. Six serotypes (1-6) of CVB are recognized: CVB1, CVB2, CVB3, CVB4, CVB5, and CVB6. CVB can cause a variety of diseases, including gastrointestinal illness, myocarditis, pneumonia, aseptic meningitis, encephalitis, and hepatitis.
• the present disclosure provides coxsackievirus B (CVB) compositions and methods of use of such compositions to induce an immune response to CVB in an individual.
• CVB coxsackievirus B
• FIG. 1 provides an amino acid sequence of a CVB4-encoded polyprotein (SEQ ID NO:1).
• FIG. 2 depicts viral neutralizing titer (VNT) to CVB1 through CVB 5 in serum of vaccinated human subjects at one month after the last dose.
• VNT viral neutralizing titer
• FIG. 3 depicts peak VNT for each CVB serotype (CVB 1 -CVB 5).
• FIG. 4-13 depict VNT to CVB 1 (FIG. 4 and FIG. 5), CVB2 (FIG. 6 and FIG. 7), CVB3
• FIG. 8 and FIG. 9 depicts CVB -neutralizing antibody levels in baseline seronegative subjects following vaccination with a CVB composition.
• FIG. 15 depicts enterovirus-specific absolute IgG levels in serum of subjects following vaccination with a CVB composition. Data include serum levels during the vaccination period and up to 6 months after the last dose. Data are represented as enzyme immunoassay units (EIU).
• EIU enzyme immunoassay units
• FIG. 16 depicts enterovirus-specific IgG levels in serum of subjects following vaccination with a CVB composition represented as fold increases in enterovirus-specific IgG levels over the levels measured at baseline for each individual.
• FIG. 17 depicts the CVB -neutralizing antibody titers in all subjects (baseline seropositive and baseline seronegative) in serum of subjects following vaccination with a CVB composition. Data includes titers during the vaccination period and up to 6 months after the last dose. Titers are represented in a logarithmic (log2) scale.
• FIG. 18 depicts VNT in the serum of baseline seronegative individuals following vaccination with a CVB composition.
• the terms “individual” and “patient” are used interchangeably herein to refer to an individual (e.g., a human) being treated using a method of the present disclosure.
• Treating,” and “treatment,” as used herein, refers to the treatment of the disease or condition of interest in a mammal, e.g., a human, having the disease or condition of interest, and includes, for example: (i) inhibiting or decreasing the severity of the disease or condition, or one or more symptoms thereof, e.g., arresting or slowing development or progression of the disease or condition, and/or ameliorating one or more symptoms; (ii) relieving the disease or condition, i.e., causing regression of the disease or condition, or one more symptoms thereof; and/or (iii) stabilizing the disease or condition.
• polypeptide refers to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.
• the term includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues; immunologically tagged proteins; and the like.
• polynucleotide and “nucleic acid,” used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides.
• this term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.
• neutralizing antibody or “viral neutralizing antibody” (VNT) is meant an antibody which either is purified from, or is present in, serum and which recognizes a specific antigen (e.g., a CVB -encoded polypeptide) and inhibits the infectivity of CVB and the effect(s) of the CVB in the host (e.g., a human).
• a specific antigen e.g., a CVB -encoded polypeptide
• the present disclosure provides coxsackievirus B (CVB) compositions and methods of use of such compositions to induce an immune response to CVB in an individual.
• CVB coxsackievirus B
• CVB compositions where such compositions are also referred to herein as “immunogenic compositions.”
• a CVB composition of the present disclosure can induce an immune response in an individual to one or more CVB serotypes.
• a CVB composition of the present disclosure can include whole CVB or portions of CVB.
• the term “CVB composition” includes: a) inactivated viral particles (IVP); b) a CVB viral-like particle (VLP); c) a CVB subunit (e.g., one or more CVB polypeptides); and d) one or more nucleic acids comprising nucleotide sequences encoding one or more CVB polypeptides.
• CVB-encoded polypeptides include VP1, VP2, VP3, VP4, 2A, 2B, 2C, 3A, 3B, 3C, and 3D.
• a “CVB composition” can comprise one or more CVB-encoded polypeptides, or a nucleic acid comprising a nucleotide sequence encoding one or more CVB-encoded polypeptides.
• a composition comprising “CVB” refers to a composition comprising CVB I VPs, CVB VLPs, one or more CVB polypeptides, or nucleic acid(s) comprising nucleotide sequences encoding one or more CVB polypeptides.
• Coxsackie B virus (CVB; also referred to herein and in the literature as “Coxsackie B virus” or “CBV”) is a group of 6 serotypes of Coxsackievirus (CVB1-CVB6).
• a composition of the present disclosure includes CVB (in the form of CVB IVPs, CVB VLPs, CVB polypeptides, or nucleic acid(s) comprising nucleotide sequences encoding one or more CVB polypeptides) of all 6 serotypes; i.e., in some cases, a composition of the present disclosure in need thereof includes CVB1, CVB2, CVB3, CVB4, CVB5, and CVB6.
• a composition of the present disclosure in need thereof includes only 5 serotypes.
• a composition of the present disclosure includes CVB1, CVB2, CVB3, CVB4, and CVB5, but not CVB6.
• a composition of the present disclosure includes only a single CVB serotype.
• a composition of the present disclosure includes only CVB1.
• a composition of the present disclosure includes only CVB2.
• a composition of the present disclosure includes only CVB3.
• a composition of the present disclosure includes only CVB4.
• a composition of the present disclosure includes only CVB5.
• a composition of the present disclosure includes CVB of only 2 different serotypes (e.g., CVB1 and CVB2; CVB1 and CVB 3; CVB1 and CVB4; CVB1 and CVB5; CVB2 and CVB3; CVB2 and CVB4; CVB2 and CVB5; CVB3 and CVB4; CVB3 and CVB5; or CVB4 and CVB5) and does not include CVB of any other serotype.
• CVB1 and CVB2 e.g., CVB1 and CVB2; CVB1 and CVB 3; CVB1 and CVB4; CVB1 and CVB5; CVB2 and CVB3; CVB2 and CVB4; CVB2 and CVB5; CVB3 and CVB4; CVB3 and CVB5; or CVB4 and CVB5
• CVB1 and CVB2 e.g., CVB1 and CVB2; CVB1 and CVB 3; CVB1 and CVB4; CVB1
• a composition of the present disclosure includes CVB of only 3 different serotypes (e.g., CVB1, CVB2, and CVB3; CVB1, CVB2, and CVB4; CVB1, CVB2, and CVB5; CVB1, CVB3, and CVB4; CVB1, CVB3, and CVB5; CVB2, CVB3, and CVB4; CVB2, CVB3, and CVB5; CVB3, CVB4, and CVB5) and does not include CVB of any other serotype.
• CVB1, CVB2, and CVB3; CVB1, CVB2, and CVB4; CVB1, CVB2, and CVB5; CVB1, CVB3, and CVB5; CVB3, CVB4, and CVB5 e.g., CVB1, CVB2, and CVB3; CVB1, CVB2, and CVB4; CVB1, CVB2, and CVB5; CVB1, CVB3, and CVB5; CVB3, CVB4, and CVB5; and does not include CVB of any other serotype.
• a composition of the present disclosure includes CVB of only 4 different serotypes (e.g., the composition may exclude: CVB3 and CVB6; CVB4 and CVB6; CVB5 and CVB6; other any other combination of 2 CVB serotypes).
• a composition of the present disclosure does not include any enterovirus other than CVB.
• a composition of the present disclosure does not include any whole virus, inactivated virus, viral protein (e.g., viral subunit), or nucleic acid encoding a viral protein, of an enterovirus other than CVB.
• a composition of the present disclosure comprises CVB of one or more serotypes, where the CVB is in “inactivated” form, which means that the infectivity of the virus has been reduced or eliminated.
• the term as used herein also includes viruses that are replication defective.
• a replication defective virus is a virus defective for a constitutive protein. Such a virus can enter the cell, deliver the partial genome, translate the proteins encoded and replicate the genome but cannot encapsidate new particles. Thus, it cannot spread to neighboring cells or tissue.
• Inactivated CVB may be produced by propagating the virus in cell culture and by purifying it from infected cells and culture media by high-speed centrifugation in a density gradient formed by sucrose or other high-density media.
• the virus may be purified by chromatography.
• the infectivity of the purified viruses can be destroyed by inactivating the viruses by chemical treatment (e.g. formalin inactivation like that used to produce inactivated polio virus vaccine), irradiation or heat treatment.
• Replication defective viruses may be prepared by physical or genetic inactivation e.g., by deleting a structural gene in the viral genome, and producing a complementing cell line constitutively expressing the protein encoded by the gene deleted in order to replicate the defective virus.
• a composition of the present disclosure comprises formalin-inactivated CVB IVPs.
• a composition of the present disclosure comprises CVB of from two to five serotypes, wherein the CVB is the form of IVPs, CVB VLPs, one or more CVB polypeptides, or one or more nucleic acids comprising a nucleotide sequence(s) encoding the one or more CVB polypeptides, wherein the composition comprises two or more of:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 2.5 x 10 8 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 1.5 x 10 9 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 2.5 x 10 8 IVP;
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• a composition of the present disclosure comprises CVB of from two to five serotypes, wherein the CVB is the form of IVPs, CVB VLPs, one or more CVB polypeptides, or one or more nucleic acids comprising a nucleotide sequence(s) encoding the one or more CVB polypeptides, wherein the composition comprises two or more of:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• the amounts of CVB can be in a volume of from about 75 pL to about 150 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, or from about 140 pL to about 150 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL
• a composition of the present disclosure comprises CVB of from two to five serotypes, wherein the CVB is the form of IVPs, CVB VLPs, one or more CVB polypeptides, or one or more nucleic acids comprising a nucleotide sequence(s) encoding the one or more CVB polypeptides, wherein the composition comprises two or more of:
• CVB1 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• CVB4 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• VLP aqueous lipid-containing polypeptide
• CVB adenosine-containing polypeptide
• nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• the amounts of CVB can be in a volume of from about 400 pL to about 450 pL, from about 450 pL to about 500 pL, from about 500 pL to about 550 pL, or from about 550 pL to about 600 pL.
• the composition comprises the amounts of CVB in a volume of 500 pL.
• the composition does not include CBV6.
• composition of the present disclosure comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• the amounts of CVB can be in a volume of from about 75 pL to about 150 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, or from about 140 pL to about 150 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL
• CVB1 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• CVB2 in an amount of from 1.0 x 10 7 IVP to 2.0 x 10 7 IVP;
• CVB4 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• the amounts of CVB can be in a volume of from about 75 pL to about 150 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, or from about 140 pL to about 150 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL
• composition of the present disclosure comprises:
• the amounts of CVB can be in a volume of from about 75 pL to about 150 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, or from about 140 pL to about 150 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL
• composition of the present disclosure comprises:
• CVB4 1.6 x 10 8 IVP
• CVB5 4.8 x 10 8 IVP, or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• the amounts of CVB can be in a volume of from about 400 pL to about 450 pL, from about 450 pL to about 500 pL, from about 500 pL to about 550 pL, or from about 550 pL to about 600 pL.
• the composition comprises the amounts of CVB in a volume of 500 pL.
• the composition does not include CBV6.
• composition of the present disclosure comprises:
• CVB5 3.1 x 10 8 IVP, or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• the amounts of CVB can be in a volume of from about 400 pL to about 450 pL, from about 450 pL to about 500 pL, from about 500 pL to about 550 pL, or from about 550 pL to about 600 pL.
• the composition comprises the amounts of CVB in a volume of 500 pL.
• the composition does not include CBV6.
• a composition of the present disclosure comprises: [0085] a) CVB1 in an amount of from 2.0 x 10 7 IVP to 2.5 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 2.5 x 10 8 IVP;
• CVB can be in a volume of from about 75 pL to about 600 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, from about 140 pL to about 150 pL, from about 150 pL to about 200 pL, from about 200 pL to about 250 pL, from about
• CVB1 in an amount of from about 1 pg protein to about 50 pg protein (e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25 pg to 30 pg, from 30 pg to 35 pg, from 35 pg to 40 pg, from 40 pg to 45 pg, or from 45 pg to 50 pg);
• pg protein e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25
• CVB2 in an amount of from about 1 pg protein to about 50 pg protein (e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25 pg to 30 pg, from 30 pg to 35 pg, from 35 pg to 40 pg, from 40 pg to 45 pg, or from 45 pg to 50 pg);
• pg protein e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25
• CVB3 in an amount of from about 1 pg protein to about 50 pg protein (e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25 pg to 30 pg, from 30 pg to 35 pg, from 35 pg to 40 pg, from 40 pg to 45 pg, or from 45 pg to 50 pg);
• pg protein e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25
• CVB4 in an amount of from about 1 pg protein to about 50 pg protein (e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25 pg to 30 pg, from 30 pg to 35 pg, from 35 pg to 40 pg, from 40 pg to 45 pg, or from 45 pg to 50 pg); and
• CVB5 in an amount of from about 1 pg protein to about 50 pg protein (e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 pg to 20 pg, from 20 pg to 25 pg, from 25 pg to 30 pg, from 30 pg to 35 pg, from 35 pg to 40 pg, from 40 pg to 45 pg, or from 45 pg to 50 pg), for a total amount of protein of from about 5 pg to about 250 pg.
• pg protein e.g., from about 1 pg to 2 pg, from 2 pg to 3 pg, from 3 pg to 5 pg, from 5 pg to 10 pg, from 10 pg to 15 pg, from 15 p
• the amounts of protein can be in a volume of from about 75 pL to about 600 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, from about 140 pL to about 150 pL, from about 150 pL to about 200 pL, from about 200 pL to about 250 pL, from about 250 pL to about 300 pL, from about 300 pL to about 350 pL, from about 350 pL to about 400 pL, from about 400 pL to about 450 pL, from about
• composition of the present disclosure comprises:
• CVB1 in an amount of from about 2 pg protein to about 4 pg protein
• CVB2 in an amount of from about 1 pg protein to about 2.5 pg protein
• CVB3 in an amount of from about 2 pg protein to about 4 pg protein
• CVB4 in an amount of from about 1 pg protein to about 2 pg protein
• CVB5 in an amount of from about 1 pg protein to about 2.5 pg protein, for a total amount of protein of about from about 8 pg protein to about 15 pg protein.
• the amounts of protein can be in a volume of from about 75 pL to about 150 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, or from about 140 pL to about 150 pL).
• the composition comprises the amounts of CVB in a volume of 100 pL.
• the composition comprises the amounts of CVB in
• composition of the present disclosure comprises:
• CVB5 in an amount of 2.3 pg protein, for a total amount of protein of about 10.7 pg.
• the amounts of protein can be in a volume of from about 75 pL to about 150 pL (e.g., from about 75 pL to about 80 pL, from about 80 pL to about 85 pL, from about 85 pL to about 90 pL, from about 90 pL to about 110 pL, from about 95 pL to about 105 pL, from about 95 pL to about 100 pL, from about 100 pL to about 110 pL, from about 110 pL to about 120 pL, from about 120 pL to about 130 pL, from about 130 pL to about 140 pL, or from about 140 pL to about 150 pL.
• the composition comprises the amounts of CVB in a volume of 100 pL. In some cases, the composition does not include CBV6.
• composition of the present disclosure comprises:
• CVB1 in an amount of from about 10 pg protein to about 20 pg protein
• CVB2 in an amount of from about 5 pg protein to about 12.5 pg protein
• CVB4 in an amount of from about 5 pg protein to about 10 pg protein
• CVB5 in an amount of from about 5 pg protein to about 12.5 pg protein, for a total amount of protein of about from about 35 pg protein to about 75 pg protein.
• the amounts of CVB can be in a volume of from about 400 pL to about 450 pL, from about 450 pL to about 500 pL, from about 500 pL to about 550 pL, or from about 550 pL to about 600 pL.
• the composition comprises the amounts of CVB in a volume of 500 pL. In some cases, the composition does not include CBV6.
• composition of the present disclosure comprises:
• CVB1 in an amount of 14 pg protein
• CVB2 in an amount of 8.5 pg protein
• CVB5 in an amount of 11.5 pg protein, for a total amount of protein of 53.5 pg.
• the amounts of CVB can be in a volume of from about 400 pL to about 450 pL, from about 450 pL to about 500 pL, from about 500 pL to about 550 pL, or from about 550 pL to about 600 pL.
• the composition comprises the amounts of CVB in a volume of 500 pL. In some cases, the composition does not include CBV6.
• a composition of the present disclosure when administered to an individual, induces a viral neutralizing antibody titer (VNT) of from 1/8 to 1/64,000, as determined by a VNT assay. In some cases, such VNT is a peak VNT (e.g., as depicted in FIG. 3). In some cases, a composition of the present disclosure, when administered to an individual, induces a VNT of from about 1/2,000 to about 1/4,000, as determined by a VNT assay. In some cases, a composition of the present disclosure, when administered to an individual, induces a VNT of from about 1/10 to about 1/500, as determined by a VNT assay.
• VNT viral neutralizing antibody titer
• a composition of the present disclosure when administered to an individual, induces a VNT of from about 1/500 to about 1/1,000, as determined by a VNT assay. In some cases, a composition of the present disclosure, when administered to an individual, induces a VNT of from about 1/1,000 to about 1/2,000, as determined by a VNT assay. In some cases, a composition of the present disclosure, when administered to an individual, induces a VNT of from about 1/2,000 to about 1/4,000, as determined by a VNT assay. In some cases, a composition of the present disclosure, when administered to an individual, induces a VNT of from about 1/4,000 to about 1/8,000, as determined by a VNT assay.
• a composition of the present disclosure when administered to an individual, induces a VNT of from about 1/8,000 to about 1/10,000, as determined by a VNT assay. In some cases, a composition of the present disclosure, when administered to an individual, induces a VNT of from about 1/10,000 to about 1/20,000, as determined by a VNT assay.
• viral neutralizing antibody titer refers to the highest dilution of the sample which still neutralizes the infectivity of the virus in cell culture.
• the viral neutralizing titer (VNT) is calculated as the last serum dilution that reduces the number of plaques by at least 80% using a plaque reduction assay.
• a VNT of 1/2,000 refers to the amount of antibody in a serum sample wherein, when the sample is diluted by more than 1/2,000 (“a 2,000 VNT”), no longer neutralizes CVB in the sample.
• VNT viral neutralizing antibody titer
• 2,000 means a 2000x dilution (referred to as “1/2,000” or a “2,000 VNT”) is the highest dilution that reduces infection of a cell in culture by at least 80%; and “4,000” means a 4000x dilution (referred to as “1/4,000” or a “4,000 VNT”) is the highest dilution that reduces infection of a cell in culture by at least 80%.
• a single dose of a subject composition is administered to an individual.
• the VNT against CVB in an individual at 14 days post-administration of the single dose of the composition is increased by 8- to 10-fold relative to a control.
• the VNT against CVB in an individual at 14 days post-administration of the single dose of the composition is increased by 3- to 10-fold relative to a control.
• a control refers to: i) the VNT against CVB in the individual before administration of the single dose of a composition of the present disclosure; or ii) a reference control level of VNT against CVB.
• a first dose of a subject composition is administered to an individual; and a second dose of a subject composition is administered to the individual at a time that is after the first dose (e.g., the second dose is administered from 7 days to 3 weeks, from 7 days to 2 weeks, from 2 weeks to 1 month, from 1 month to 2 months, from 2 months to 3 months, or from 3 months to 6 months, after the first dose).
• a first dose of a subject composition is administered to an individual; and a second dose of a subject composition is administered to the individual 1 month after the first dose.
• a first dose of a subject composition is administered to an individual; and a second dose of a subject composition is administered to the individual 2 months after the first dose.
• a first dose of a subject composition is administered to an individual; and a second dose of a subject composition is administered to the individual 3 months after the first dose.
• the VNT against CVB in an individual at 14 days post-administration of the second dose of the composition is increased by 8- tolO-fold relative to a control.
• the VNT against CVB in an individual at 14 days post-administration of the second dose of the composition is increased by 3- to 10-fold relative to a control.
• a control refers to: i) the VNT against CVB in the individual before administration of the first dose of a composition of the present disclosure; or ii) a reference control level of VNT against CVB.
• a neutralizing titer is produced by neutralizing antibody against CVB as measured in serum of the subject.
• an effective dose of a composition of the present disclosure is sufficient to produce a viral neutralization titer (VNT) of at least 100.
• an effective dose of a composition of the present disclosure is sufficient to produce a VNT of from 100 to 500.
• an effective dose of a composition of the present disclosure is sufficient to produce a VNT of more than 500.
• an effective dose of a composition of the present disclosure is sufficient to produce a 500-1,000 VNT.
• an effective dose of a composition of the present disclosure is sufficient to produce a 1000-10,000 VNT.
• an effective dose of a composition of the present disclosure is sufficient to produce a 1000-2000, 1000-3000, 1000-4000, 1000- 5000, 1000-6000, 1000-7000, 1000-8000, 1000-9000, 1000-10,000, 2000-3000, 2000-4000, 2000-5000, 2000-6000, 2000-7000, 2000-8000, 2000-9000, 2000-10,000, 3000-4000, 3000-5000, 3000-6000, 3000- 7000, 3000-8000, 3000-9000, 3000-10,000, 4000-5000, 4000-6000, 4000-7000, 4000-8000, 4000-9000, 4000-10,000, 5000-6000, 5000-7000, 5000-8000, 5000-9000; 5000-10,000, 6000-7000, 6000-8000, 6000-9000, 6000-10,000, 7000-8000, 7000-9000, 7000-10,000, 8000-9000, 8000-10,000, or a 9000- 10,000 VNT.
• an effective dose of a composition of the present disclosure is sufficient to produce a 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 11000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19000, 20,000 or higher VNT.
• VNT is produced 1-72 hours post administration.
• VNTs may be produced 1-10, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-72, 10-20, 10-30, 10-40, 10-50, 10- 60, 10-70, 10-72, 20-30, 20-40, 20-50, 20-60, 20-70, 20-72, 30-40, 30-50, 30-60, 30-70, 30-72, 40-50, 40-60, 40-70, 40-72, 50-60, 50-70, 50-72, 60-70, 60-72, or 70-72 hours post administration.
• VNTs may be produced 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 56, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, or 72 hours post administration.
• VNT is produced within 14 days of administration of a composition of the present disclosure.
• VNT is produced within 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days of administration of a composition of the present disclosure.
• a VNT of from 1/8 to 1/64,000 is maintained for a period of time of at least 24 weeks, at least 32 weeks, at least 40 weeks, at least 52 weeks, or more than 52 weeks, following administration of one or more doses of a CVB composition of the present disclosure.
• the VNT comprises IgG isotype antibodies (e.g., the VNT comprises at least 50%, at least 60%, at least 75%, at least 85%, or more than 85%, IgG isotype antibodies).
• the VNT comprises IgG isotype antibodies, IgM isotype antibodies, and IgA isotype antibodies.
• VNT can be determined using a VNT assay (also referred to as a “plaque reduction assay”).
• a VNT assay also referred to as a “plaque reduction assay”.
• the presence of neutralizing antibodies blocks the infectivity of the virus into cells.
• serum obtained from an individual is diluted to various degrees.
• the diluted serum is mixed with a certain amount of infectious virus (e.g., 30-100 plaque forming units (PFU) of the virus, where PFU represents one infective virus particle) optimized for each virus serotype, and the mixture is incubated for a certain period of time (e.g., first for 60 min at 37°C followed by overnight (approximately 18 hours) incubation) at room temperature.
• infectious virus e.g., 30-100 plaque forming units (PFU) of the virus, where PFU represents one infective virus particle
• the mixture is added to a monolayer of cells (e.g., green monkey kidney cells (GMK-AH-1 cells; RRID:CVCL...L878)) and the cell monolayer is incubated with the mixture for a certain period of time (e.g., for 40-48 hours). After this incubation, the number of virus-induced plaques on the monolayer is counted, e.g., after staining the cells or by microscopic examination of the cells.
• a mixture of virus and hyperimmune serum raised against the enterovirus serotype in question e.g., serum raised in monkeys or horses
• Virus without serum serves as a negative control.
• the neutralizing titer (VNT) is calculated as the last serum dilution which reduces the number of plaques by at least 80%. See, e.g., Boone and Albrecht (1983) J. Virol. Methods 6:193.
• a composition of the present disclosure may include whole CVB viruses, the infectivity of which has been inactivated, or subunit vaccines containing certain antigenic structures, proteins or peptides of the virus, or their combination (such as virus like particles), or fragments of viral RNA or cDNA encoding the whole virus or individual viral proteins or inactivated forms of the virus.
• a composition of the present disclosure comprises a component of a CVB.
• the “component” may be an immunogenic polypeptide of the virus such as a subunit thereof including a chimeric subunit, or a nucleic acid fragment such as part of the genome of the virus.
• the component may also be recombinantly or synthetically produced or modified.
• Subunit vaccines may consist of purified viral proteins or recombinant viral proteins, synthetic peptides corresponding to viral antigenic epitopes, VLPs, or empty viral capsids, which are produced during infection but lack the viral genome. These subunit vaccines can be administered either as such or conjugated to haptens or carriers (e.g., ISCOM particles, chitosan, TLR agonists, biodegradable microparticles).
• haptens or carriers e.g., ISCOM particles, chitosan, TLR agonists, biodegradable microparticles.
• a composition of the present disclosure can include a CVB subunit, e.g., one or more CVB polypeptides.
• CVB-encoded polypeptides include VP1, VP2, VP3, VP4, 2A, 2B, 2C, 3A, 3B, 3C, and 3D.
• the composition can comprise one or more CVB polypeptides, where the one or more CVB polypeptides comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence for the whole virus polyprotein (for example the CVB4 polyprotein shown in FIG.
• the initial 73 amino acids of the CVB4 polyprotein in FIG. 1, forms the CBV4 VP4 component of the virus upon maturation of the polyprotein.
• the composition can comprise any CBV4 VP4 polypeptide comprising an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity with either the full amino acid sequence or with a polypeptide fragment of the mature form of CBV4 VP4.
• the VLP can be formed using full-length viral proteins, truncated forms of the full-length viral proteins, or fusion proteins that contain a part of the viral protein.
• a composition suitable for administration to an individual in need thereof can include one or more nucleic acids comprising a nucleotide sequence(s) encoding one or more CVB polypeptides.
• Suitable nucleic acids include recombinant expression vectors.
• the one or more nucleic acids are recombinant expression vectors comprising one or nucleotide sequences encoding one or more CVB polypeptides.
• the recombinant expression vector is a DNA or RNA molecule comprising a nucleotide sequence encoding a gene product (e.g., an RNA or a polypeptide) of interest.
• Recombinant expression vectors include viral expression vectors (e.g.
• the recombinant expression vector is a recombinant lentivirus vector.
• the recombinant expression vector is a recombinant HIV vector.
• the recombinant expression vector is a recombinant adenovirus vector.
• the recombinant expression vector is a recombinant AAV vector.
• the nucleotide sequence(s) encoding the one or more CVB polypeptides is operably linked to one or more transcriptional control elements, such as a promoter.
• the nucleotide sequence encoding the gene product of interest is operably linked to a promoter that is functional in a mammalian cell, e.g., a muscle cell, an epithelial cell, a dendritic cell, an antigen-presenting cell, and the like.
• RNA molecules comprising one or more nucleotide sequences encoding one or more CVB polypeptides.
• the one or more RNA molecules comprise at least one 5’ cap structure and/or a 5’ untranslated region (5’ UTR).
• the one or more RNA molecules also comprise a 3’ UTR and/or a 3’ tailing sequence (e.g., a poly(adenosine) (poly-A) sequence).
• Examples of 5’ cap structures include inosine, Nl- methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA- guanosine, and 2-azido-guanosine.
• the one or more RNA molecules comprises one or more of: a nucleoside base modification, a sugar modification, and a backbone modification.
• the composition comprises, in addition to the one or more RNA molecules, one or both of: a) a polymer (e.g., polyethylene glycol, poly glycolide, polyvinyl alcohol, polyvinyl pyrrolidone, polylactide, poly(lactide-co-glycolide) (PLGA), polycaprolactone, polysorbate, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide), poloxamer, poloxamine, poly(oxyethylated) glycerol, poly(oxyethylated) sorbitol, poly(oxyethylated) glucose, polyethyleneimine, polyamidoamine (PAMAM) dendrimer, and block copolymer poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) (PEG-b- PLGA)); and b) a lipid.
• a polymer e.g., polyethylene glycol, poly glycolide,
• a composition suitable for administering to an individual in need thereof comprises one or more RNA molecules (e.g., mRNA) comprising one or more nucleotide sequences encoding one or more CVB polypeptides.
• the one or more RNA molecules are administered to an individual in need thereof in an amount such that the level of the encoded CVB polypeptide(s) in the serum of the individual is at least 50 pg/mL at least 2 hours after administration.
• the one or more RNA molecules are administered to an individual in need thereof in an amount such that the level of the encoded CVB polypeptide(s) in the serum of the individual remains above 50 pg/mL for at least 72 hours after administration.
• each of the one or more mRNAs is administered in an amount of from about 1 pg to about 200 pg, e.g., from about 1 pg to about 5 pg, from about 5 pg to about 10 pg, from about 10 pg to about 15 pg, from about 15 pg to about 20 pg, from about 20 pg to about 25 pg, from about 25 pg to about 30 pg, from about 30 pg to about 40 pg, from about 40 pg to about 50 pg, from about 50 pg to about 60 pg, from about 60 pg to about 70 pg, from about 70 pg to about 80 pg, from about 80 pg to about 90 pg, from about 90 pg to about 100 pg, from about 100 pg to about 125 pg, from about 125 pg to about 150 pg, from about 150 pg to about 175 pg, or
• a composition of the present disclosure includes nucleic acids (e.g., mRNAs) encoding CVB1, CVB2, CVB3, CVB4, and CVB5, but not CVB6, where each of the mRNAs is present in the composition in an amount of from about 1 pg to about 200 pg, e.g., from about 1 pg to about 5 pg, from about 5 pg to about 10 pg, from about 10 pg to about 15 pg, from about 15 pg to about 20 pg, from about 20 pg to about 25 pg, from about 25 pg to about 30 pg, from about 30 pg to about 40 pg, from about 40 pg to about 50 pg, from about 50 pg to about 60 pg, from about 60 pg to about 70 pg, from about 70 pg to about 80 pg, from about 80 pg to about 90 pg, from about 90 p
• a composition of the present disclosure includes a nucleic acid (e.g., an mRNA) encoding polypeptides of only a single CVB serotype.
• a composition of the present disclosure includes nucleic acids encoding only CVB1 polypeptides.
• a composition of the present disclosure includes nucleic acids encoding only CVB2 polypeptides.
• a composition of the present disclosure includes nucleic acids encoding only CVB3 polypeptides.
• a composition of the present disclosure includes nucleic acids encoding only CVB4 polypeptides.
• a composition of the present disclosure includes nucleic acids encoding only CVB5 polypeptides.
• the nucleic acid encoding only polypeptides of a single CVB serotype is mRNA, and the mRNA is present in the composition in an amount of from about 1 pg to about 200 pg, e.g., from about 1 pg to about 5 pg, from about 5 pg to about 10 pg, from about 10 pg to about 15 pg, from about 15 pg to about 20 pg, from about 20 pg to about 25 pg, from about 25 pg to about 30 pg, from about 30 pg to about 40 pg, from about 40 pg to about 50 pg, from about 50 pg to about 60 pg, from about 60 pg to about 70 pg, from about 70 pg to about 80 pg, from about 80 pg to about 90 pg, from about 90
• a composition of the present disclosure includes nucleic acids (e.g., mRNA) encoding CVB polypeptides of only 2 different serotypes (e.g., CVB1 and CVB2; CVB1 and CVB3; CVB1 and CVB4; CVB1 and CVB5; CVB2 and CVB3; CVB2 and CVB4; CVB2 and CVB5; CVB3 and CVB4; CVB3 and CVB5; or CVB4 and CVB5) and does not include a nucleic acid encoding CVB polypeptides of any other serotype.
• nucleic acids e.g., mRNA
• the nucleic acids encoding polypeptides of only two CVB serotypes are mRNAs, and each of the mRNAs are present in the composition in an amount of from about 1 pg to about 200 pg, e.g., from about 1 pg to about 5 pg, from about 5 pg to about 10 pg, from about 10 pg to about 15 pg, from about 15 pg to about 20 pg, from about 20 pg to about 25 pg, from about 25 pg to about 30 pg, from about 30 pg to about 40 pg, from about 40 pg to about 50 pg, from about 50 pg to about 60 pg, from about 60 pg to about 70 pg, from about 70 pg to about 80 pg, from about 80 pg to about 90 pg, from about 90 pg to about 100 pg, from about 100 pg to about 125 pg, from about 125
• a composition of the present disclosure includes nucleic acids (e.g., mRNA) encoding CVB polypeptides of only 3 different serotypes (e.g., CVB1, CVB2, and CVB3; CVB1, CVB2, and CVB4; CVB1, CVB2, and CVB5; CVB1, CVB3, and CVB4; CVB1, CVB3, and CVB5; CVB2, CVB3, and CVB4; CVB2, CVB3, and CVB5; CVB3, CVB4, and CVB5) and does not include nucleic acid encoding CVB polypeptides of any other serotype.
• nucleic acids e.g., mRNA
• CVB1, CVB2, and CVB3 e.g., CVB1, CVB2, and CVB4; CVB1, CVB2, and CVB5; CVB1, CVB3, and CVB4; CVB1, CVB3, and CVB5; CVB2, CVB3, and CVB5; CVB3, CVB4, and CVB5
• the nucleic acids encoding polypeptides of only 3 CVB serotypes are mRNAs, and each of the mRNAs are present in the composition in an amount of from about 1 pg to about 200 pg, e.g., from about 1 pg to about 5 pg, from about 5 pg to about 10 pg, from about 10 pg to about 15 pg, from about 15 pg to about 20 pg, from about 20 pg to about 25 pg, from about 25 pg to about 30 pg, from about 30 pg to about 40 pg, from about 40 pg to about 50 pg, from about 50 pg to about 60 pg, from about 60 pg to about 70 pg, from about 70 pg to about 80 pg, from about 80 pg to about 90 pg, from about 90 pg to about 100 pg, from about 100 pg to about 125 pg, from about 125
• a composition of the present disclosure includes nucleic acids encoding CVB polypeptides of only 4 different serotypes (e.g., the composition may exclude nucleic acids encoding polypeptides of: CVB3 and CVB6; CVB4 and CVB6; CVB5 and CVB6; other any other combination of 2 CVB serotypes).
• CVBs, subunits, VLPs, or nucleic acids can be formulated into a pharmaceutical composition, which in addition to the active ingredients that elicit immune stimulation may comprise pharmaceutically acceptable excipients, carriers, haptens and/or adjuvants.
• Excipients, carriers, haptens and adjuvants may include for example phenoxyethanol, magnesium chloride, sucrose, thiomersal, formaldehyde, phenol, antibiotics (preservatives) or aluminum salts, polymer microparticles, ISCOM particles, carrier proteins (e.g. cholera toxin), liposomes, protein micelles (haptens/adjuvants), or TLR agonists.
• a CVB composition can include an adjuvant (e.g., an immunostimulating amount of an adjuvant).
• a CVB composition can include an immune- stimulating amount of an adjuvant.
• suitable adjuvants that can be used in humans include, but are not necessarily limited to, alum, aluminum phosphate, aluminum hydroxide, MF59 (4.3% w/v squalene, 0.5% w/v Tween 80TM, 0.5% w/v Span 85), CpG-containing nucleic acid (where the cytosine is unmethylated), QS21, monophosphoryl lipid A (MPL), 3-Q-desacyl-4'-monophosphoryl lipid A (3DMPL), extracts from Aquilla, immune- stimulating complexes (ISCOMS; complexes of cholesterol, phospholipids, and Quillaja saponins), LT/CT mutants, poly(D,L-lactide-co-glycolide) (PLG) microparticles, Quil A
• thr-MDP N-acetyl-muramyl-E-threonyl-D-isoglutamine
• CGP 11637 N-acetyl-nor- muramyl-E-alanyl-D-isoglutamine
• nor-MDP N-acetylmuramyl-E-alanyl-D- isoglutaminyl-E-alanine-2-(r-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine
• CGP 19835A referred to as MTP-PE
• RIBI which contains three components extracted from bacteria: monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPE+TDM+CWS) in a 2% squalene/Tween 80 emulsion.
• MPE+TDM+CWS cell wall skeleton
• Further exemplary adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59TM (see, e.g., WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer E121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RIBITM adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.
• cytokines such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), etc.), interferons (e.g. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) e.g.
• MPL monophosphoryl lipid A
• 3dMPL 3-O-deacylated MPL
• GB-2220221, EP-A-0689454 optionally in the substantial absence of alum when used with pneumococcal saccharides e.g. WO 00/56358; (6) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions (see, e.g.
• WO 99/52549 WO 99/52549
• a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol WO 01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (WO 01/21152);
• a saponin and an immunostimulatory oligonucleotide e.g. a CpG oligonucleotide
• an immunostimulant and a particle of metal salt see, e.g.
• WO 00/23105 (12) a saponin and an oil-in-water emulsion (see e.g. WO 99/11241); (123) a saponin (e.g. QS21)+3dMPL+IM2 (optionally including a sterol) (see, e.g. WO 98/57659); (14) other substances that act as immunostimulating agents to enhance the efficacy of the composition.
• a saponin and an oil-in-water emulsion see e.g. WO 99/11241
• a saponin e.g. QS21
• 3dMPL+IM2 optionally including a sterol
• Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl- normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutarninyl-L- alanine-2-(r-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.
• thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
• nor-MDP N-25 acetyl- normuramyl-L-alanyl-D-isoglutamine
• Matrix-MTM is an adjuvant that comprises 40 nm nanoparticles comprising Quillaja saponins, cholesterol, and phospholipid.
• Adjuvants suitable for administration to a human are of particular interest. In some cases, the adjuvant is one that enhances a CD4 + T helper response to the immunogen.
• a poly inosine: cytosine (poly I:C) nucleic acid is also suitable for use.
• Poly I:C is a synthetic double-stranded RNA
• a cyclic dinucleotide activator of the STING pathway is also suitable for use.
• Suitable cyclic dinucleotide adjuvants include, but are not limited to: 1) bis-(3’,5’)-cyclic dimeric adenosine monophosphate (c-di-AMP); 2) bis-(3’,5’)-cyclic dimeric guanosine monophosphate (c-di-GMP); and bis-(3’,5’)-cyclic dimeric inosine monosphosphate (c-di-IMP). Also suitable for use is poly(I:C).
• the effectiveness of an adjuvant may be determined by one or more of: i) measuring the amount of antibodies directed against the immunogenic antigen or antigenic epitope thereof (e.g., using a VNT assay as described above); ii) measuring a cytotoxic T lymphocyte response to the antigen; and iii) measuring a helper T cell response to the antigen.
• a composition of the present disclosure may comprise a pharmaceutically acceptable excipient, a variety of which are known in the art and need not be discussed in detail herein.
• Pharmaceutically acceptable excipients have been amply described in a variety of publications, including, for example, “Remington: The Science and Practice of Pharmacy”, 19 th Ed. (1995), or latest edition, Mack Publishing Co; A. Gennaro (2000) “Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H.C. Ansel et al., eds 7 th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) A.H. Kibbe et al., eds., 3 rd ed. Amer. Pharmaceutical Assoc.
• a pharmaceutical composition can comprise a pharmaceutically acceptable excipient.
• a subject pharmaceutical composition will be suitable for administration to a subject, e.g., will be sterile.
• a subject pharmaceutical composition will be suitable for administration to a human subject, e.g., where the composition is sterile and is free of detectable pyrogens and/or other toxins.
• the protein compositions may comprise other components, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
• the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, hydrochloride, sulfate salts, solvates (e.g., mixed ionic salts, water, organics), hydrates (e.g., water), and the like.
• composition of the present disclosure is a liquid composition.
• the present disclosure provides compositions (e.g., liquid compositions, including pharmaceutical compositions) comprising CVB, as described above.
• a composition of the present disclosure comprises: a) CVB, as described above; and b) saline (e.g., 0.9% NaCl).
• the composition is sterile.
• the composition is suitable for administration to a human subject, e.g., where the composition is sterile and is free of detectable pyrogens and/or other toxins.
• the present disclosure provides a composition
• a composition comprising: a) CVB, as described above; and b) saline (e.g., 0.9% NaCl), where the composition is sterile and is free of detectable pyrogens and/or other toxins.
• the present disclosure provides methods of inducing an immune response to CVB in an individual.
• the methods comprise administering to an individual in need thereof an effective amount of a composition of the present disclosure.
• a composition of the present disclosure is referred to below as an “immunogenic composition.”
• the present disclosure provides methods of reducing the likelihood that an individual will develop an acute CVB infection.
• the methods comprise administering to an individual in need thereof an effective amount of a composition of the present disclosure.
• the present disclosure provides methods of reducing the likelihood that an individual will develop a CVB infection-associated disease and/or symptoms of a CVB infection.
• the methods comprise administering to an individual in need thereof an effective amount of a composition of the present disclosure.
• An immunogenic composition as described above can be administered parenterally by injection (e.g., intramuscularly or subcutaneously), orally, perorally, intradermally, transcutaneously, sublingually, intranasally, nasopharyngeally, via inhalation, or per rectum.
• a prime-boost vaccine protocol is used.
• a first (priming) immunogenic composition is administered, and, after a time, a second (booster) immunogenic composition is administered.
• a second immunogenic composition can be administered at a time period of from 1 day to 1 year following administration of the first immunogenic composition.
• a second immunogenic composition can be administered at a time period of from 1 day to 1 week, from 1 week to 2 weeks, from 2 weeks to 1 month, from 1 month to 2 months, from 2 months to 6 months, or from 6 months to 1 year following administration of the first immunogenic composition.
• a method of the present disclosure can induce an immune response in an individual to CVB.
• a method of the present disclosure can induce an immune response in an individual to one or more of CVB1, CVB2, CVB3, CVB4, and CVB5.
• a method of the present disclosure can induce an immune response in an individual to CVB1, CVB2, CVB3, CVB4, and CVB5.
• a method of the present disclosure can decrease the likelihood of an acute infection with CVB.
• a method of the present disclosure can reduce the likelihood that an individual will develop a CVB infection-associated disease (e.g., CVB-induced gastrointestinal illness, myocarditis, pneumonia, aseptic meningitis, encephalitis, or hepatitis).
• a method of the present disclosure can ameliorate one or more adverse symptoms of a CVB infection.
• a method of the present disclosure treats one or more of CVB-induced gastrointestinal illness, myocarditis, pneumonia, aseptic meningitis, encephalitis, and hepatitis.
• a method of the present disclosure can reduce the likelihood that the individual will develop T1D.
• a method of the present disclosure can reduce the likelihood that the individual will develop celiac disease.
• an individual suitable for treatment according to the present disclosure is from 1 month to 3 months old (e.g., 1 month, 2 months, or 3 months old). In some cases, an individual suitable for treatment according to the present disclosure is from 3 months to 5 years of age. In some cases, an individual suitable for treatment according to the present disclosure is from 3 months to 6 months, from 6 months to 1 year, from 1 year to 2 years, or from 2 years to 5 years of age. In some cases, an individual suitable for treatment according to the present disclosure is from 5 years to 11 years of age. In some cases, an individual suitable for treatment according to the present disclosure is from 12 years to 17 years of age. In some cases, an individual suitable for treatment according to the present disclosure is from 18 years to 25 years of age. In some cases, an individual suitable for treatment according to the present disclosure is older than 25 years.
• the individual is greater than 6 years older, two years or older, six years or older, 12 years or older, 18 years or older, 30 years or older, between about 6 years and 12 years old, between about 6 years old and about 30 years old, between about 12 and about 30 years old, or between about 18 and about 30 years.
• the individual is a pregnant woman.
• an individual suitable for treatment according to the present disclosure is immunologically naive with respect to CVB; i.e., the individual has low or undetectable neutralizing antibody to CVB.
• an individual suitable for treatment according to the present disclosure has previously been exposed (e.g., via natural infection) to CVB and has detectable antibody titer to CVB.
• the individual is at risk (e.g., at greater risk than the general population) of developing type 1 diabetes (T1D).
• T1D type 1 diabetes
• Individuals at risk (e.g., at greater risk than the general population) of developing T1D include individuals who have been genetically determined to be at increased risk for developing T1D, e.g., individuals with an HLA-conferred susceptibility to T1D, especially carriers of the HLA DR3 and/or DR4 alleles.
• T1D Individuals at risk (e.g., at greater risk than the general population) of developing T1D include mothers or children with HLA-conferred disease susceptibility to T1D, especially carriers of the HLA DR3 and/or DR4 alleles; individuals with T1D in first or second-degree relatives; and individuals (e.g., children) testing positive for two or more diabetes-associated autoantibodies.
• a subject method reduces the likelihood that an individual will develop T1D.
• the individual is at risk (e.g., at greater risk than the general population) of developing celiac disease.
• Such individuals include individuals have a genetic predisposition to developing celiac disease; and individuals who have tested positive for celiac-associated autoantibodies.
• the individual is a carrier of an HLA-DR3 allele.
• a composition comprising coxsackievirus B (CVB) of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (I VP), viral-like particles (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides,
• CVB1 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• CVB3 in an amount of from 5.0 x 10 8 IVP to 1.5 x 10 9 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides,
• composition does not include CVB6.
• composition of aspect 1, wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• VLP VLP
• CVB polypeptides VLP
• nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides
• composition of aspect 2, wherein the composition comprises:
• CVB1 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• CVB2 in an amount of from 1.0 x 10 7 IVP to 2.0 x 10 7 IVP;
• CVB4 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• a composition comprising coxsackievirus B (CVB) of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (IVP), a CVB viral-like particle (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides wherein the composition, when administered to an individual, induces viral neutralizing antibody titer (VNT) of from 1/8 to 1/64,000 as determined by a VNT assay, wherein the composition does not include CVB6.
• CVB coxsackievirus B
• IVP inactivated viral particles
• VLP CVB viral-like particle
• nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides
• VNT viral neutralizing antibody titer
• composition of aspect 4 wherein the composition comprises CVB of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (IVP), wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB2 in an amount of from 1.0 x 10 7 IVP to 3.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• VLP a volume of 100 pL; or
• CVB1 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• CVB3 in an amount of from 5.0 x 10 8 IVP to 1.5 x 10 9 IVP;
• CVB4 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• CVB5 in an amount of from 2.0 x 10 8 IVP to 4.0 x 10 8 IVP, [00211] or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, [00212] in a volume of 500 pL.
• composition of aspect 5, wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• Aspect 7 The composition of aspect 6, wherein the composition comprises:
• CVB1 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• CVB2 in an amount of from 1.0 x 10 7 IVP to 2.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 2.0 x 10 8 IVP;
• CVB4 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• Aspect 8 The composition of any one of aspects 1-7, wherein the IVP are formalin inactivated.
• Aspect 9 The composition of any one of aspects 1-8, wherein the composition comprises an adjuvant.
• Aspect 10 The composition of any one of aspects 1-8, comprising saline.
• Aspect I L A method of inducing an immune response to coxsackievirus B (CVB) in an individual, the method comprising administering to the individual a composition of any one of aspects 1- 10.
• CVB coxsackievirus B
• Aspect 12 The method of aspect 11, wherein the composition is administered intramuscularly.
• Aspect 13 The method of aspect 11, wherein the composition is administered subcutaneously.
• Aspect 14 A method of reducing the likelihood that an individual will develop an acute coxsackievirus B (CVB) infection, the method comprising administering to the individual a composition of any one of aspects 1-10.
• Aspect 15 The method of any one of aspects 11-14, wherein the individual is a neonate.
• Aspect 16 The method of any one of aspects 11-14, wherein the individual is a pregnant woman.
• Aspect 17 The method of any one of aspects 11-14, wherein the individual is at increased risk of developing type 1 diabetes.
• Aspect 18 The method of any one of aspects 11-14, wherein the individual is at increased risk of developing celiac disease.
• Aspect 19 The method of any one of aspects 11-14, wherein the individual is a carrier of an HLA DR3 and/or an HLA DR4 allele.
• Aspect 20 The method of any one of aspects 11-14, wherein the individual was seropositive for viral neutralizing titer to one or more of CVB1, CVB2, CVB3, CVB4, and CVB5 prior to said administering.
• Aspect 21 The method of any one of aspects 11-14, wherein the individual was seronegative for viral neutralizing titer to one or more of CVB1, CVB2, CVB3, CVB4, and CVB5 prior to said administering.
• a composition comprising coxsackievirus B (CVB) of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (I VP), viral-like particles (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB5 in an amount of from 4.0 x 10 7 IVP to 8.0 x 10 7 IVP, [00249] or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides,
• CVB1 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• CVB4 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides,
• CVB 1 protein in an amount of from 1 pg to 50 pg;
• CVB2 protein in an amount of from 1 pg to 50 pg;
• CVB3 protein in an amount of from 1 pg to 50 pg;
• CVB4 protein in an amount of from 1 pg to 50 pg
• CVB5 protein in an amount of from 1 pg to 50 pg
• composition does not include CVB6.
• composition of aspect 1, wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB2 in an amount of from 1.0 x 10 7 IVP to 3.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides,
• composition of aspect 2, wherein the composition comprises:
• CVB1 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 2.0 x 10 8 IVP;
• CVB4 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP; and [00279] e) CVB5 in an amount of from 6.0 x 10 7 IVP to 6.0 x 10 7 IVP,
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• Aspect 4 The composition of aspect 1, wherein the composition comprises:
• VLP VLP
• CVB polypeptides VLP
• nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides
• composition of aspect 1, wherein the composition comprises:
• VLP a volume of 500 pL.
• composition of aspect 1, wherein the composition comprises:
• Aspect 7 The composition of aspect 1, wherein the composition comprises:
• a composition comprising coxsackievirus B (CVB) of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (I VP), a CVB viral-like particle (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides wherein the composition, when administered to an individual, induces viral neutralizing antibody titer (VNT) of from 1/8 to 1/64,000 as determined by a VNT assay, wherein the composition does not include CVB6.
• CVB coxsackievirus B
• I VP inactivated viral particles
• VLP CVB viral-like particle
• nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides
• VNT viral neutralizing antibody titer
• composition 9 The composition of aspect 8, wherein the composition comprises CVB of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (I VP), wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• VLP aqueous lipid-containing polypeptide
• CVB polypeptides a polypeptide that polypeptides
• nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, [00320] in a volume of 100 pL; or
• CVB1 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• CVB4 in an amount of from 1.0 x 10 8 IVP to 2.5 x 10 8 IVP;
• CVB5 in an amount of from 2.0 x 10 8 IVP to 4.0 x 10 8 IVP; or
• CVB 1 protein in an amount of from 1 pg to 50 pg;
• CVB2 protein in an amount of from 1 pg to 50 pg;
• CVB3 protein in an amount of from 1 pg to 50 pg;
• CVB4 protein in an amount of from 1 pg to 50 pg
• CVB5 protein in an amount of from 1 pg to 50 pg
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, [00334] in a volume of 500 pL.
• composition of aspect 9, wherein the composition comprises:
• CVB1 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 3.0 x 10 8 IVP;
• CVB4 in an amount of from 2.0 x 10 7 IVP to 5.0 x 10 7 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• composition 11 The composition of aspect 10, wherein the composition comprises:
• CVB1 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• CVB3 in an amount of from 1.0 x 10 8 IVP to 2.0 x 10 8 IVP;
• CVB4 in an amount of from 3.0 x 10 7 IVP to 4.0 x 10 7 IVP;
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides.
• composition of aspect 9, wherein the composition comprises:
• VLP or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, [00356] in a volume of 100 pl.
• composition 13 The composition of aspect 9, wherein the composition comprises:
• CVB5 in an amount of 3.1 x 10 8 IVP, [00363] or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, [00364] in a volume of 500 pL.
• composition of aspect 9, wherein the composition comprises:
• composition of aspect 9, wherein the composition comprises:
• Aspect 16 The composition of any one of aspects 1-5 and 8-13, wherein the IVP are formalin inactivated.
• Aspect 17 The composition of any one of aspects 1-16, wherein the composition comprises an adjuvant.
• Aspect 18 The composition of any one of aspects 1-17, comprising saline.
• Aspect 19 A method of inducing an immune response to coxsackievirus B (CVB) in an individual, the method comprising administering to the individual a composition of any one of aspects 1- 18.
• CVB coxsackievirus B
• Aspect 20 The method of aspect 19, wherein the composition is administered intramuscularly.
• Aspect 21 The method of aspect 19, wherein the composition is administered subcutaneously.
• Aspect 22 A method of reducing the likelihood that an individual will develop an acute coxsackievirus B (CVB) infection or a CVB infection-associated disease, the method comprising administering to the individual a composition of any one of aspects 1-18.
• CVB acute coxsackievirus B
• Aspect 23 The method of any one of aspects 19-22, wherein the individual is a neonate.
• Aspect 24 The method of any one of aspects 19-22, wherein the individual is a pregnant woman.
• Aspect 25 The method of any one of aspects 19-22, wherein the individual is at increased risk of developing type 1 diabetes.
• Aspect 26 The method of any one of aspects 19-22, wherein the individual is at increased risk of developing celiac disease.
• Aspect 27 The method of any one of aspects 19-22, wherein the individual is a carrier of an HLA DR3 and/or an HLA DR4 allele.
• Aspect 28 The method of any one of aspects 19-22, wherein the individual was seropositive for viral neutralizing titer to one or more of CVB1, CVB2, CVB3, CVB4, and CVB5 prior to said administering.
• Aspect 29 The method of any one of aspects 19-22, wherein the individual was seronegative for viral neutralizing titer to one or more of CVB1, CVB2, CVB3, CVB4, and CVB5 prior to said administering.
• Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pl, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m., intramuscular(ly); i.p., intraperitoneal(ly); s.c., subcutaneous(ly); and the like.
• Example 1 Induction of VNT in human subjects
• a composition comprising CVB of serotypes 1-5 was administered to normal, healthy human volunteers. Two cohorts were randomized in a 3 to 1 fashion to receive either 100 pL or 500 pL of the composition, or a matching placebo. Subjects received 3 doses at monthly intervals. Analysis of VNT was conducted after all subjects completed 3 doses, and 1 month of follow up after the last dose.
• the composition is a formalin-inactivated vaccine comprising CVB serotypes 1 through 5 in the form of inactivated viral particles (IVP). IVP is equivalent to RNA copy number.
• the 100 pF (“low dose”) composition included CVB1-CVB5 in the following amounts:
• the 500 pL (“high dose”) composition included CVB1-CVB5 in the following amounts:
• SAEs treatment-emergent serious adverse events
• AESI treatment-emergent adverse events of special interest
• VNT virus neutralizing titers
• FIG. 4-13 provide mean (+/- standard deviation) curves of anti-CVB virus neutralizing antibody titer by visit, baseline seroconversion and serotype.
• FIG. 4-13 depict VNT to CVB 1 (FIG. 4 and FIG. 5), CVB2 (FIG. 6 and FIG. 7), CVB3 (FIG. 8 and FIG. 9), CVB4 (FIG. 10 and FIG. 11), and CBV5 (FIG. 12 and FIG. 13) in serum of vaccinated human subjects.
• the subjects were either seropositive for VNT to the indicated CVB serotype before vaccination (FIG. 4, 6, 8, 10, and 12) or seronegative before vaccination (FIG. 5, 7, 9, 11, and 13).
• the response rate of the vaccinated human subjects was assessed.
• Responders were defined as either: a) subjects who are seronegative at baseline and who seroconvert (i.e., VNT > 1/4) at any post-vaccination time point; or b) subjects who are positive for antibodies at baseline (i.e., subjects who have pre-existing antibodies) and have a 4-fold or greater increase in VNT at any post-vaccination time point.
• FIG. 17 depicts the CVB -neutralizing antibody titer in all subjects (baseline seropositive and baseline seronegative). The titers are presented in a logarithmic (log2) scale. In addition to the time- and dose- response, the durability of the response at Week 32 is apparent for all serotypes in the vaccine. [00417] The data show durability of VNT responses against all strains of CVB in the vaccine (CVB1-5). At this 6-month post-last administration final time point (Week 32), the percent of subjects in the high dose PRV-01 arm who maintained high titers of VNT against 4 serotypes was 100%, and 90% for all 5 serotypes included in the vaccine. These data confirmed the durability of the response.
• Evidence of VNT cross-reactivity was observed against CVB6, the less common CVB serotype not included in the CVB vaccine composition.
• commercial ELISA assays showed dose- and time- dependent durable IgG responses after the switch from initial robust IgM responses, as well as partial IgA responses (which indicate a degree of mucosal immunity).
• a composition comprising CVB of serotypes 1-5 was administered to normal, healthy human volunteers. Two cohorts were randomized in a 3 to 1 fashion to receive either 100 pL or 500 pF of the composition, or a matching placebo. Subjects received 3 doses at monthly intervals. Analysis of VNT was conducted after all subjects completed 3 doses. A final analysis was conducted 6 months following the last dose of the vaccine (week 32 of the study).
• the composition is a formalin-inactivated vaccine comprising CVB serotypes 1 through 5 in the form of IVP.
• IgG anti-CVB antibodies were produced in a dose-dependent fashion.
• the data demonstrate the durability of the IgG response at week 32. Similar data were obtained for IgM.
• FIG. 18 shows dose-dependent generation of high titers of VNT for all serotypes (CVB1, CVB2, CVB3, CVB4, and CVB5).
• CVB1, CVB2, CVB3, CVB4, and CVB5 are serotypes of all serotypes.
• 100% of the subjects had neutralizing antibody titers of 1/8 or more against at least 4 serotypes, and no less than 90% of the subjects had neutralizing antibody titers of 1/8 or more against all 5 serotypes included in the vaccine.
• Neutralizing antibodies were measured against CVB6 and Coxsackievirus A9 (CAV9), using a plaque neutralization antibody assay. Neutralizing antibodies were analyzed from the baseline serum sample taken at the time of the first vaccination as well as from samples taken a month after the 3rd vaccination.
• An immunogenic composition therefore could be a vaccine that is based in 1 to 5 CVB strains but that raises protection against one or more of the CVB strains that were not on the vaccine.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Virology (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Mycology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Gastroenterology & Hepatology (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Dermatology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (5)

Applications Claiming Priority (6)

Publications (1)

Family

ID=86158933

Family Applications (1)

Country Status (5)

Cited By (1)

Citations (1)

Family Cites Families (1)

• 2022
  • 2022-10-24 WO PCT/US2022/078581 patent/WO2023076856A1/en not_active Ceased
  • 2022-10-24 EP EP22888412.8A patent/EP4422680A4/en active Pending
  • 2022-10-24 JP JP2024523853A patent/JP2024540976A/ja active Pending
  • 2022-10-24 IL IL312205A patent/IL312205A/en unknown
  • 2022-10-24 US US18/703,256 patent/US20250352634A1/en active Pending

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events